Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

摘要

To the Editor: Worldwide, lung cancer, particularly non-small cell lung cancer (NSCLC), is the leading cause of tumor-related death. Cost-effectiveness analysis show no economic benefits for advanced NSCLC patients over chemotherapy.[1] Furthermore, tests such as programmed cell death ligand 1 (PD-L1) and tumor mutational burden (TMB) tests, evaluated via immunohistochemical methods and next-generation sequencing, respectively, are widely used for screening potential beneficiaries of immune checkpoint inhibitors (ICIs). However, these two methods have different predictive values, making their comprehensive evaluation the focus of the current controversy.